We previously reported that destruction of the small ubiquitin-like modifier (SUMO) modification site in the axonal collapsin response mediator protein 2 (CRMP2) was sufficient to selectively decrease trafficking of the voltage-gated sodium channel Na V 1.7 and reverse neuropathic pain. Here, we further interrogate the biophysical nature of the interaction between CRMP2 and the SUMOylation machinery, and test the hypothesis that a rationally designed CRMP2 SUMOylation motif (CSM) peptide can interrupt E2 SUMO-conjugating enzyme Ubc9-dependent modification of CRMP2 leading to a similar suppression of Na V 1.7 currents. Microscale thermophoresis and amplified luminescent proximity homogeneous alpha assay revealed a low micromolar binding affinity between CRMP2 and Ubc9. A heptamer peptide harboring CRMP2's SUMO motif, also bound with similar affinity to Ubc9, disrupted the CRMP2-Ubc9 interaction in a concentration-dependent manner. Importantly, incubation of a tat-conjugated cellpenetrating peptide (t-CSM) decreased sodium currents, predominantly Na V 1.7, in a model neuronal cell line. Dialysis of t-CSM peptide reduced CRMP2 SUMOylation and blocked surface trafficking of Na V 1.7 in rat sensory neurons. Fluorescence dye-based imaging in rat sensory neurons demonstrated inhibition of sodium influx in the presence of t-CSM peptide; by contrast, calcium influx was unaffected. Finally, t-CSM effectively reversed persistent mechanical and thermal hypersensitivity induced by a spinal nerve injury, a model of neuropathic pain. Structural modeling has now identified a pocket-harboring CRMP2's SUMOylation motif that, when targeted through computational screening of ligands/molecules, is expected to identify small molecules that will biochemically and functionally target CRMP2's SUMOylation to reduce Na V 1.7 currents and reverse neuropathic pain.
Inhibition of the Ubc9 E2 SUMO-conjugating enzyme-CRMP2 interaction decreases Na V 
Introduction
SUMOylation is an adenosine triphosphate (ATP)-dependent posttranslational modification where a small ubiquitin-like modifier (SUMO) protein is covalently bound to a lysine residue in target proteins exhibiting a SUMO-interaction motif, CKXE/D, C being a large hydrophobic amino acid. 73 Similar to ubiquitination, SUMO conjugation is achieved by different enzymes, E1-activating (SAE1/ UBA2 complex), E2-conjugating (Ubc9), and various E3 ligases. SUMOylation has been described in numerous cellular processes, including nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle, 33 and is an important regulator of neuronal and synaptic function. 34 Small ubiquitin-like modifier targets several cytosolic and plasma membrane proteins, including ion channels, to regulate plasma membrane depolarization or neurotransmission by modulating their stability, subcellular targeting, transport, or interacting properties. 53, 54, 72 Collapsin response mediator protein 2 (CRMP2) is a tetrameric protein, which specifies axon/dendrite fate and axonal outgrowth, 37, 42 and was shown, using sequence alignment and structure analysis, to be SUMOylated on Lysine 374. 20 We demonstrated that SUMOylation of CRMP2 at site 374 is dependent on phosphorylation at Serine 522 by cyclin-dependent kinase 5 (Cdk5), 19 which is believed to disrupt CRMP2 tetramer toward a monomeric state, thus exposing the SUMOylation site. 20 SUMOylation of CRMP2 specifically controls trafficking and surface expression of the tetrodotoxin-sensitive voltage-gated sodium channel Na V 1.7. 10, 19, 21 Decreasing CRMP2 SUMOylation, using CRMP2 mutants with disrupted SUMO motifs, reduced Na V 1.7 currents. As inferred from human pain disorders, Na V 1.7 is a major contributor to nociception and pain signaling. Gain-of-function mutations in Na V 1.7 increase neuronal excitability and underlie pain disorders, whereas loss-of-function mutations render individuals insensitive to painful stimuli. 14, 24, 83, 91 The potential of targeting Na V 1.7 in pain is highlighted by many patents filed and clinical trials being conducted (see Ref. 23) . As pan Na V 1.x blockers have a potent analgesic effect, there is a vital need for Na V 1.7-specific treatment, which is lacking in many Na V 1.7 drugdevelopment programs.
Targeting Na V 1.7 indirectly, but specifically, through modulation of CRMP2 SUMOylation has been demonstrated to be a promising avenue for experimental neuropathic pain treatment. 64 In the chronic model of spared nerve injury (SNI), CRMP2 SUMOylation was increased, and reducing deSUMOylation of CRMP2, by expressing CRMP2 K374A in vivo, significantly reversed SNI mechanical allodynia. 64 Consequently, we postulated that (1) CRMP2 interacts with Ubc9 and (2) disruption of this interaction using a CRMP2 SUMO peptide would specifically reduce Na V 1.7 sodium current, resulting in a relief of neuropathic pain. 10 Here, we assessed binding between the Ubc9 E2 SUMOconjugating enzyme and CRMP2 using microscale thermophoresis and determined that CRMP2 and Ubc9 interact directly and with low micromolar affinity. Using rational design, we identified a heptamer peptide containing the CRMP2 SUMOylation consensus site fused to the transduction domain of the HIV-1 tat protein, called t-CSM, to disrupt the CRMP2-Ubc9 interaction. This t-CSM peptide inhibited CRMP2 SUMOylation, Na V 1.7 membrane trafficking, and specifically inhibited Na V 1.7 sodium influx in sensory neurons. Intrathecal injection of t-CSM reversed nerve injury-induced thermal and mechanical hypersensitivity with no sedation or motor impairment in rats.
Methods

Animals
Adult male and female Sprague-Dawley rats (pathogen-free male 250-275 g, female 200-225 g; Envigo, Placentia, CA) or female mice (C57BL/6NHsd, 20-24 g; Envigo) were kept in light (12-hour light: 12-hour dark cycle; lights on at 07:00 hours)-controlled and temperature (23 6 3˚C)-controlled rooms. Standard rodent chow and water were available ad libitum. University of Arizona's College of Medicine Institutional Animal Care and Use Committee (IACUC) approved these protocols. All experiments were performed congruent with the National Institutes of Health's Guide for Care and Use of Laboratory Animals and per the ethical guidelines reported by the International Association for the Study of Pain. Treatment and control groups consisted of randomly assigned animals, and experimenters were blinded to the grouping information until the analysis was completed.
Materials
The CRMP2 SUMOylation motif (CSM) peptide chemically linked to the cell-penetrating motif of the HIV transactivator of transcription peptide tat (t-CSM; YGRKKRRQRRRGKMDENQ; tat sequence identified by the underlined text) was manufactured and high-performance liquid chromatography purified by Genscript USA Inc (Piscataway, NJ), and was resuspended in doubledistilled water or dimethyl sulfoxide (DMSO) (Sigma-Aldrich, St. Louis, MO), aliquoted, and stored at 220˚C. Several of our studies previously showed the lack of effect of both scramble and random peptides fused with different cell-penetrating motifs in both in vitro and in vivo studies. 4, 26, 40, 70 All chemicals, unless stated otherwise, were purchased from Sigma-Aldrich. Fura-2 low-affinity and sodium-binding benzofuran isophthalate acetoxymethyl ester (SBFI-AM) was obtained from Teflabs (Austin, TX). Catecholamine A-differentiated (CAD) (ECACC Cat# 08100805) cells, of mouse origin, were grown in cell culture conditions at 37˚C in 5% CO 2 . Catecholamine A-differentiated cells were grown in DMEM/F12 media supplemented with 10% fetal bovine serum (hyclone) and 1% penicillin/streptomycin sulfate from 10,000-mg/mL stock. Catecholamine A-differentiated cells were chosen as a model neuron cell line because of ;80% contribution by Na V 1.7 to total sodium currents as determined by isoformspecific blockade of Na V 1.7 by both ProTox-II (Sigma) and Huwentoxin-IV (Alomone Laboratories, Jerusalem, Israel).
20,21
Coimmunoprecipitation and immunoblotting
Coimmunoprecipitation experiments were performed on spinal cord lysates from adult Sprague-Dawley rats using lysates homogenized in radioimmunoprecipitation assay buffer as described previously. 26 Samples were then processed by immunoblotting as described. 4, 5 Blots were probed with anti-Ubc9 (Catalogue# ab21193; Abcam, Cambridge, United Kingdom), or anti-CRMP2 (Catalogue# 2993; Sigma-Aldrich) (both 1:1000). At least 3 blots were performed per experiment.
Purification of recombinant human CRMP2-His and Ubc9-GST
Recombinant human CRMP2-His was expressed and purified as described previously. 26 The pure CRMP2 protein was concentrated to 30 mg/mL, flash frozen in liquid nitrogen, and stored at 2 80˚C. Ubc9-GST fusion protein was expressed and purified as previously described in. 30 
Microscale thermophoresis
Microscale thermophoresis (MST), an assay that monitors the thermophoretic movement of molecules in optically generated microscopic temperature gradients thereby permitting analysis of biomolecular interaction, was performed as described previously. 86, 87 In MST, increasing concentrations of unlabeled ligand are mixed with the fluorescently labeled biomolecule that is kept at a constant concentration. Purified CRMP2-His was fluorescently labelled with a His-Tag labeling kit RED-Tris-NTA (Nanotemper, München, Germany) per manufacturer's instructions. Two hundred nanomolar of CRMP2-His (in phosphate-buffered saline (PBS) supplemented with 0.05% Tween-20 [PBS-T buffer]) was mixed with 1M NT-647-His-labeling dye. After a 30-minute incubation at room temperature (RT), the labeled CRMP2 was pelleted by centrifugation at 15,000g for 10 minutes at 4˚C. Fifty nanoMolar of NT-647-CRMP2 was mixed with different concentrations of Ubc9-GST in PBS-T and incubated at RT for 10 minutes. The thermophoresis readouts were captured on a Monolith NT.115 (Nanotemper) using premium MST capillaries, at 40% light-emitting diode and 40% MST power. Measurements were performed in triplicates. Data analysis was performed with the MO Affinity Analysis software (Nanotemper) using the K d model (standard fitting model derived from law of mass action).
by PerkinElmer (Waltham, MA). After a first mix of 200 nM of Ubc9-GST with 800 nM of CRMP2-GST, 10 mL of donor, and 15 mL of acceptors beads (both at 10 mg/mL) were added and incubated for 1 hour. The reaction was read at an emission wavelength of 615 nm using an excitation wavelength of 680 nm, on a PerkinElmer EnVision plate reader.
Immunoprecipitation of endogenously SUMOylated proteins and CRMP2 from cell lysate
Catecholamine A-differentiated cells, treated with 20-mM t-CSM peptide (or control, ie, 0.01% DMSO) overnight, were lysed into the immunoprecipitation buffer exactly as previously described.
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Immunoblotting was performed with an anti-CRMP2 antibody (Catalogue #2993; Sigma) on samples immune-captured by immunoprecipitation with a SUMO1 antibody (Catalogue #S8070; Sigma).
Patch clamp electrophysiology
Whole-cell voltage clamp recordings were performed at RT on CAD cells using an EPC 10 Amplifier (HEKA Electronics; Holliston, MA) exactly as described previously. 20, 21 2.9. Primary dorsal root ganglion neuronal cultures Dorsal root ganglions (DRGs) from all levels were acutely dissociated using methods as described previously. 26 Rat DRG neurons were isolated from Sprague-Dawley rats using previously developed procedures. 
Sodium fluorescence imaging
Sodium fluorescence imaging of rat cultured DRG neurons grown for 4 days in vitro (4 DIV) was performed exactly as described before. 6 Changes in cytosolic Na 1 concentration ([Na 1 ] c ) were examined using the Na 1 -sensitive dye SBFI-AM (Molecular Probes, Eugene, OR). Neurons were loaded with 9-mM SBFI-AM for 1 hour at 37˚C. [Na 1 ] c was calculated using equations 32 as described previously, 16 assuming a dissociation constant of 15.7 mM for SBFI. The fluorescence intensity for each cell was quantified and normalized to the area of the region of interest using NiS elements software. To obtain the region of interest, the perimeter of each neuron was manually traced.
Spared nerve injury model of neuropathic pain
The biceps femoris muscle was dissected to bare the 3 terminal branches of the sciatic nerve to create the SNI as described previously. 15 Sham animals also underwent the same operation; however, the nerves were exposed and not ligated. Before any testing, animals were allowed to recover for 5 to 7 days.
Indwelling intrathecal catheter
Rats were sedated using a xylazine/ketamine/(12/80 mg/kg intraperitoneal; Sigma-Aldrich) and placed in a stereotaxic head holder. After the exposition and incision of the cisterna magna, an 8-cm catheter (PE-10; Stoelting) was implanted as previously reported. 89 
Testing of allodynia
The assessment of tactile allodynia was performed exactly as reported before using the "up and down" method described before. 9 Data were expressed as the mean withdrawal threshold.
Writhing test
The acetic acid-induced writhing test is a model of visceral pain where a chemical irritant, acetic acid, is injected intraperitoneally, inducing abdominal contractions and extension of back limbs, collectively defined as "writhes." 55 Animals were first allowed to acclimate with the clear plexiglas chamber used for the experiment during 15 minutes or until explorative behavior ceased. Mice were then immediately injected in the peritoneum of the left lower quadrant of the abdomen with 300 mL of 1% acetic acid in normal saline, through a 27-gauge needle. After the acetic acid injection, mice were placed in the testing chamber and their subsequent nociceptive behavior was recorded and scored (in an investigator blinded manner): writhing behavior was assessed between 5 and 25 minutes after the injection. t-CSM peptide (4 mg or the vehicle 0.1% DMSO in the control group) was administered intrathecally (in a volume of 10 mL), 60 minutes before the acetic acid injection.
Rotarod
A week after surgical placement of the intrathecal catheters, the rats were trained and then assessed (every 30 minutes for 3 hours) for their capability to stay on a rotating rod after intrathecal delivery of peptide (or vehicle) as described before. 71 For SNI rats, training consisted of 2 training sessions on a nonrotating rotarod followed by 2 training sessions where the rotarod was set at 4 and 8 rpm, respectively, after intrathecal injection of t-CSM or vehicle as indicated. Testing was performed on an accelerating rotarod (4-40 rpm, 5 minutes) and repeated every half hour for the first hour after drug administration and every hour for 4 more hours for a total of 5 hours. 
Data analysis
Statistical significance was determined using GraphPad Software (LaJolla, CA). Student t test or a 1-or 2-way analysis of variance followed by post hoc comparisons (Dunnett or Tukey test) was used to assess the statistical significance of differences between mean values. Results were stated as significant when the corresponding P value was less than 0.05.
Results
Ubc9 interacts directly with CRMP2
We previously reported that the CRMP2 protein sequence has a canonical c-K-X-E/D SUMOylation motif, which accommodates E2-conjugating enzyme Ubc9-mediated addition of SUMO. 20, 21 Here, we asked whether, during the course of SUMOylation, CRMP2 interacts with Ubc9. In this study, coimmunoprecipitation experiments revealed an interaction between Ubc9 and CRMP2 in CAD cells (Fig. 1) .
Microscale thermophoresis was used to test whether there is direct binding between CRMP2 and Ubc9 using purified recombinant proteins. In MST, an infrared laser generates precise microscopic heat gradients within capillaries containing a fluorescently labeled protein (ie, CRMP2). The diffusion of labeled molecules along these temperature gradients is measured in the presence of ranging concentrations of an unlabeled ligand (Ubc9). 39, 75 As the concentration of Ubc9 increases, it binds to CRMP2 altering its thermodiffusion out of the heated infrared spot, resulting in a change in the MST signal and providing a record of the binding between CRMP2 and Ubc9 ( Fig. 2A) . As a negative control, CRMP2 was also incubated with various concentrations of GST; no association could be detected Figure 4 . t-CSM peptide disrupts the Ubc9-CRMP2 interaction as determined through ALPHA. (A) ALPHA assay schematic. The ALPHA assay signal is generated after the transfer of singlet oxygen between nickel-chelate donor beads (CRMP2-His) and a glutathione acceptor bead chelated to Ubc9-GST. (B) Black and white image of Coomassie-stained gel of 1 and 5 mg of purified CRMP2-His and Ubc9-GST (arrowheads). (C) Steady-state binding of 200-nM Ubc9-GST to 800-nM CRMP2-His over 24 hours with a stable signal over ;18 hours. In presence of both donor and acceptor beads, the ALPHA signal was always at least 500 times higher than the signal generated in absence of acceptor beads or without any beads (negative controls). For this ALPHA experiment (performed in triplicate), the signal/background ratio was ;50 with a Z' factor (index for quality control) of 0.71. (D) ALPHA signal generated by the binding of CRMP2 with ranging concentration of Ubc9. The data were fitted using the Hill method (r 2 5 0.96). The apparent K d is 0.8 6 0.2 mM. No association between CRMP2 and Ubc9 could be detected in presence of 1-mM t-CSM. Data are presented as mean 6 SEM (n 5 3). Error bars are smaller than the symbols. Figure 5 . t-CSM peptide disrupts the Ubc9-CRMP2 interaction. Microscale thermophoresis (MST) analyses was used to determine the binding between Ubc9-GST (0.003-100 mM)-labelled and NT-647-labeled CRMP2 (50 nM) in the absence (DMSO, 0.1%) or presence of increasing concentrations of t-CSM peptide. Microscale thermophoresis data were fitted as described in the Methods section. Ubc9-CRMP2 binding was reduced by t-CSM in a concentration-dependent manner: t-CSM, at 2.5 and 5 mM, reduced the binding of Ubc9-GST to CRMP2 (K d 5 80 6 14 mM and 137 6 14 mM, respectively). No association could be detected between CRMP2 and Ubc9 at 10 mM and 20 mM of t-CSM. Data are presented as mean 6 SEM (n 5 3). Error bars are smaller than the symbols. DMSO, dimethyl sulfoxide. between GST and CRMP2 (Figs. 2B and C). NT-647-labeled CRMP2 (100 nM) was mixed with varying concentrations of Ubc9 (0.003-100 mM), and apparent K d values were calculated by fitting curves using the standard fitting model derived from law of mass action. The MST experiments revealed that Ubc9 binds to CRMP2 with an apparent K d of 12.2 6 2.7 mM (Fig. 2C) . Adenosine triphosphate (1 mM), a necessary cofactor for the SUMOylation machinery, did not alter the affinity of the Ubc9/ CRMP2 interaction (Fig. 2C) . Divalent cations MgCl 2 (200 mM) or CaCl 2 (200 mM), believed to favor CRMP2 tetramerization, 51 also did not alter the K d values of the Ubc9/CRMP2 interaction (Fig.  2C) . These results establish CRMP2 as a bona fide binding partner of Ubc9.
Rational design of a CRMP2 SUMOylation motif "decoy" peptide
We previously identified CRMP2 SUMOylation as a potential biomarker for neuropathic pain. 64 In rodents inflicted with an SNI-mimicking chronic pain, CRMP2 SUMOylation was found to be increased and preventing SUMOylation of CRMP2, by expressing the SUMO-null CRMP2 K374A in vivo, significantly reversed SNI-induced mechanical allodynia. 64 The sequence GKMDENQ ( Fig. 3 ; SUMOylated lysine at position 374 underlined) in CRMP2 conforms to a canonical SUMOylation motif. 84 Reasoning that a peptide encompassing this region (CSM) could serve as a "decoy" and act as a sink for SUMOylation by Ubc9, we fused CSM to the cell-penetrating transduction domain of the HIV-1 transactivator of transcription (tat, t) creating the cell-permeable peptide t-CSM. The resulting t-CSM peptide was incubated with Ubc9 to assess binding using MST (Fig. 3D) , revealing an interaction with a K d of 0.4 6 0.1 mM.
Inhibition of Ubc9-CRMP2 interaction using t-CSM peptide
Next, we tested whether t-CSM peptide could inhibit the Ubc9-CRMP2 interaction. For this, we initially turned to the ALPHA, a bead-based assay amenable to high throughput screening and miniaturization (Fig. 4A) . 22 Briefly, we incubated purified CRMP2-His protein bound to a Ni-chelate acceptor bead and Ubc9-GST protein bound by a glutathione-coated donor bead (Fig. 4B) . If an acceptor bead comes into proximity with a donor bead, the acceptor bead emits a fluorescence signal between 520 and 620 nm. The donor bead contains a photosensitizer, phthalocyanine, that converts ambient oxygen to an excited singlet form of oxygen. This singlet oxygen will react with a thioxene derivative on the acceptor bead culminating in a chemiluminescent reaction. This reaction occurs only if the beads are within 200 nm of each other. The strength of the singlet oxygen reaction is also proportional to the amount of analyte present. In the absence of acceptor beads or any beads, no ALPHA signal was produced (Fig. 4C) . Incubating various concentrations of Ubc9 (from 0.005 to 5 mM) with 1-mM CRMP2 that gave an apparent K d of 0.8 6 0.1 mM (Fig. 4D) , this binding was stable over at least an 18-hour window. No binding could be detected between Ubc9 and CRMP2 in the presence of 10-mM t-CSM peptide; the data could not be fitted to a curve (r 2 5 0.23) (Fig. 4D) .
To test whether t-CSM could be useful in inhibiting the Ubc9-CRMP2 interaction, we performed MST analyses between CRMP2 and Ubc9 in the presence of increasing concentrations of t-CSM. Ubc9-CRMP2 binding was reduced by t-CSM in a concentration-dependent manner: 2.5-mM t-CSM reduced the binding of Ubc9-GST to CRMP2 (K d 5 80 6 14 mM), whereas 5-mM t-CSM reduced it even further (K d 5 137 6 14 mM, respectively) (Fig. 5) . No association could be detected between CRMP2 and Ubc9 at 10 and 20 mM of t-CSM (Fig. 5) . In separate pulldown experiments with bacterially produced Ubc9-GST, CRMP2 binding to Ubc9 was also reduced by t-CSM in spinal cord lysates (data not shown). Collectively, these results show that the Ubc9-CRMP2 interaction can be recapitulated both with recombinant proteins and in native tissue and that t-CSM can interfere with this interaction.
t-CSM peptide decreases SUMOylation of CRMP2 in catecholamine A-differentiated cells
Having established that t-CSM can interfere with the Ubc9-CRMP2 interaction, we next sought to investigate whether cellular dialysis of t-CSM could prevent CRMP2 SUMOylation. Because there is no known antibody that selectively identifies SUMOylated CRMP2, we performed the following experiment. We prepared lysates from CAD cells in a denaturing lysis buffer, then heat denatured them to completely unfold and disrupt noncovalent protein complexes and to inactivate SUMO isopeptidases 88 ; the mouse CAD (CNS catecholaminergic cells) neuronal cell line was chosen because they expresses high levels of Na V 1.7. 81 An immunoprecipitation was then performed with a SUMO1 antibody followed by immunoblotting with a CRMP2 antibody to detect SUMOylated CRMP2. As shown in Figures 6A-B , expression of a SUMOnull (K374A) CRMP2 or dialysis of the t-CSM "decoy" peptide decreased the amount of detectable SUMOylated CRMP2. These results demonstrate that endogenous CRMP2 SUMOylation is inhibited by the t-CSM peptide.
t-CSM peptide decreases Na 1 currents in catecholamine A-differentiated cells
We previously reported that CRMP2-K374A, a nonSUMOylated mutant of CRMP2, impairs sodium current density in CAD cells. 19, 21 If preventing CRMP2 SUMOylation was achieved by cellular dialysis of t-CSM, then we would expect Na V 1.7 current density to be diminished consistent with our published data. Current-voltage relationships in transfected CAD cells were recorded by the application of 5-millisecond step depolarizations ranging from 270 to 160 mV (in 15 mV increments) from a holding potential of 280 mV (Fig. 7A) . The transient inward current in CAD cells activated between 240 and 230 mV and reached its peak at 0 to 110 mV (Fig. 7B) . Peak inward Na 1 currents were measured and expressed as normalized peak current density to account for variations in cell size. Sodium currents were reduced to 42.5 6 5.9% (n 5 6) in CAD cells treated with 20 mM of t-CSM compared with those treated with DMSO (0.1%) (Fig. 7C) . There was no difference in Boltzmann parameters of voltage dependence of activation, half-activation voltage (V1/2), and slope factor (k) between the 2 treatment conditions (Fig. 7D) .
t-CSM attenuates ouabain-induced increase in cytosolic Na
1 in primary sensory neurons
The above data, showing t-CSM peptide inhibits Na V 1.7 currents (Fig. 8) , are consistent with our published results demonstrating diminution of Na V 1.7 currents in cell lines and in sensory neurons expressing the SUMO-null CRMP2-K374A mutant. [19] [20] [21] Notwithstanding that conventional patch clamp remains the sole technique with sufficiently high time resolution and sensitivity required for precise and direct characterization of ion channel properties, it is universally accepted that patch clamp is a slow, labor-intensive, and thus expensive technique. In anticipation of a future high throughput screening campaign for SUMOylation inhibitors of Ubc9 that we will likely identify in the ALPHA screen, we developed a low-to-medium throughput sodium fluorescence assay. Changes in cytolosolic Na 1 ([Na 1 ] c ) were monitored using the Na 1 -sensitive fluorescent dye, SBFI-AM. Ouabain, an inhibitor of Na 1 /K 1 -ATPase, was used to increase [Na 1 ] c , which was monitored using SBFI. Ouabain resulted in an increase in [Na 1 ] c (Fig. 8A) . Pretreatment of neurons with t-CSM (10 mM for 12 hours) strongly attenuated ouabain-induced increase in [Na 1 ] c (Fig.  8B) . The ouabain-induced increase in [Na 1 ] c was also inhibited by tetrodotoxin (1 mM), a pan-blocker of Na V 1.1 to Na V 1.7 channels, 44 and Protox (10 mM), a specific blocker of Na V 1.7, 74 suggesting that this increase in [Na 1 ] c is mediated by voltage-gated Na 1 channels and, specifically, by Na V 1.7 (Figs. 8C-D) . Ouabain-induced changes in [Na 1 ] c over time were quantified by calculating the area under the curve (Fig.  8E) . Taken together, the data obtained with Protox and inhibition of ouabain-induced increase in [Na 1 ] c by t-CSM suggest that this peptide reduces Na V 1.7 function as well. 
t-CSM peptide impedes membrane trafficking of Na V 1.7 in dorsal root ganglions
Next, we used immunofluorescent microscopy to determine whether t-CSM affected the subcellular localization of Na V 1.7. Sensory neurons were incubated with 20-mM t-CSM peptide and examined after live labeling of Na V 1.7 with an antibody targeting an extracellular epitope of Na V 1.7. Visual inspection of the micrographs (Fig. 9A) demonstrated that, in control cells treated with vehicle, the fluorescent signal for extracellular Na V 1.7 appeared in the vicinity of the plasma membrane of the DRG neurons. As illustrated in Figure 9A , prominent membranous Na V 1.7 staining was observed in the absence of peptide (top panel) but significantly reduced in the presence of t-CSM (bottom panel). Quantification from 30 t-CSM-treated cells revealed an ;80% reduction in surface Na V 1.7 (Fig. 9B) . Taken together, these results suggest that t-CSM-related inhibition of CRMP2 SUMOylation prevents Na V 1.7 from being targeted to the DRG neuronal membrane.
t-CSM peptide reverses neuropathic pain
Na V 1.7 is upregulated and promotes ongoing pain in animal models of chronic peripheral inflammation and in peripheral nerve injury. 43, 77 Recently, we reported that (1) Na V 1.7 upregulation in chronic neuropathic pain is accompanied by a concomitant increase in CRMP2 SUMOylation and (2) loss of CRMP2 SUMOylation, mimicked by expressing a nonSUMOylated mutant of CRMP2 (ie, CRMP2 K374A) in vivo, reversed SNI-induced mechanical allodynia. 64 Because increased Na V 1.7 after nerve injury influences the hyperexcitability of sensory neurons, which leads to neuropathic pain; here, we tested whether the "decoy peptide" based on the CSM would reverse SNI-induced mechanical allodynia. The SNI model resulted in significant mechanical and thermal hypersensitivity in both male and female rats (Fig. 10 , postsurgery group) on day 7 after injury. Spinal delivery of t-CSM (10 mg/5 mL) resulted in a significant long-lasting reversal of both thermal and mechanical hypersensitivity (Figs. 10A  and B ) that returned to the injury baseline by 24 hours. These results provide proof of concept for targeting Ubc9-CRMP2 interaction to curb Na V 1.7 activity and control nociceptive behaviors.
t-CSM does not affect visceral pain
Although inhibition of tetrodotoxin-sensitive channels was reported to block inflammatory and visceral pain, 31, 52 pharmacological block of Na V 1.7 alone in the viscera may be insufficient in targeting chronic visceral pain. 36 Therefore, we tested the potential efficacy of t-CSM in the acetic acidwrithing test wherein Na V 1.7 is predicted not to contribute. Intraperitoneal injection of acetic acid (1%) in female C57BL/ 6NHsd mice induced characteristic writhing behaviors typified by contractions of the abdomen, twisting and turning of the trunk, arching of the back, and extension of the hind limbs (Fig. 11) . In mice injected with t-CSM (i.t., 4 mg/5 mL), 1 hour Rats developed mechanical allodynia (A) and thermal hyperalgesia (B) 7 days after SNI but not with after a sham injury. Intrathecal injection (black arrow) of t-CSM (10 mg/5 mL), but not vehicle (0.01% DMSO), significantly reversed the mechanical allodynia, measured by paw withdrawal threshold (in grams), and thermal hyperalgesia, as measure by paw withdrawal latency (in seconds), for at least 6 hours after injection (n 5 6; *P , 0.05 vs preinjection baseline, 2-way ANOVA, post hoc Student-Neuman-Kuels). Brown and green symbols represent female SNI rats (n 5 6 each) treated with vehicle or t-CSM, respectively. All other symbols represent male rats. ANOVA, analysis of variance.
before the acetic acid injection, the number of observed writhing events was 35 6 7 (n 5 7), which was not different from mice pretreated spinally with 0.1% DMSO 34 6 4 (n 5 8) (Fig. 11) . Thus, t-CSM does not contribute to suppression of visceral pain.
t-CSM peptide does not induce typical motor deficit or sedation in rats
Because the current clinically used medications such as gabapentin result in severe sedation in humans, we determined whether our novel t-CSM peptide would result in similar sedative or motor impairment (ruling out false positives in pain behavioral tests based on motor reflex is of major importance). Naive male SD rats were used to determine sedation/motor impairment, so that results are not influenced by "states of injury." Rats were trained to walk on a rotating rod with a maximal cutoff time of 180 seconds before administration of peptide or vehicle. To ensure availability of the peptide in the spinal cord, we administered the drug intrathecally in these experiments. Spinal delivery of t-CSM (20 mg/5 mL i.t.) resulted in no motor impairment or sedation (Fig. 12A) because all animals remained on the rotating rod until cutoff (180 seconds) over a 24-hour period. By contrast, gabapentin, a drug known to produce severe sedation in humans, resulted in a decrease in the ability of naive rats to remain on the rotating rod (data not shown). Motor performance was not affected by t-CSM administration in rats with SNI (Fig. 12B) . Thus, using t-CSM in vivo is a safe strategy to target voltage-gated sodium channel Na V 1.7 and reverse chronic pain.
Discussion
We examined CRMP2-dependent signaling mechanisms regulating Na V 1.7 and peripheral pain transmission. We identified a novel interaction between the SUMO-conjugating E2 enzyme Ubc9 and CRMP2 and used rational design to fashion a CSM "decoy" peptide. We provide in vitro and in vivo evidence that interference of the Ubc9-CRMP2 interaction with this peptide reduces CRMP2 SUMOylation, leading to reduced Na V 1.7 currents, and mitigation of nociception in neuropathic, but not visceral, pain.
During the last decade, Na V 1.7 emerged as a high-value analgesic target. Mutations in SCN9A, the gene encoding Na V 1.7, are associated with both lowered as well as heightened sensitivities to pain. 2, 18, 38, 82 Consequently, selectively inhibiting Na V 1.7 is likely to be critical in modulating pain through pathways involving this channel. Na V 1.7-selective compounds, 13, 49, 85 peptide toxins, 90 and neutralizing antibodies 45 cause only temporary partial analgesia, and some Na V 1.7 gain-of-function mutation patients respond to pansodium channel blockers. 12, 25 The Waxman group has demonstrated a precision medicine approach, using genomics and molecular modeling, to treat pain in a handful of humans with gain-of-function mutations in Na V 1.7. 7,29 Compounds developed by Pfizer (PF-0485624 56 ) and Genentech (GX-674, which demonstrated equipotent inhibition of Na V 1.7 and Na V 1.2, and only 4-fold less potency against Na V 1. 6 1 ) have not progressed to clinic. Thus, despite significant investment into Na V 1.7 drug-development programs, there has been only marginal success. We demonstrated that elimination of the CRMP2 SUMO modification site (ie, K374) was sufficient to selectively decrease trafficking and therefore current density of Na V 1.7, but not Na V 1.1, 1.3, 1.5, 1.6, 1.8, or 1.9. 10, 19, 21 We reported a 1.78Å resolution X-ray crystal structure of mouse CRMP2, which corroborated these findings. 20 The Wood group, using an epitope-tagged Na V 1.7 mouse identified CRMP2 as part of the Na V 1.7 complex in native conditions, 41 independently confirming our findings. Congruent with these studies, here we identify a novel peptide, t-CSM, which recapitulates the reduction of sodium influx using Na V 1.7. The heptamer peptide t-CSM bound to Ubc9 with nanomolar affinity is sufficient for in vitro SUMO-1 modification by Ubc9. This finding is in line with previous publications demonstrating that heptamer peptides, containing the SUMO-1 modification consensus sequence cKXE, are sufficient for in vitro SUMO-1 modification catalyzed by Ubc9. 48, 73 Thus, these data confirm the importance of CRMP2 SUMOylation as a regulator of Na V 1.7 activity and advance targeting of the Ubc9-CRMP2 interaction as a novel mean to achieve regulation of Na V 1.7, setting the stage for future drug discovery campaigns to find selective CRMP2 SUMOylation inhibitors.
From a mechanistic viewpoint, targeting Na V 1.7-mediated pain behavior takes advantage of robust channel expression on nociceptive afferents. 17 This allows for reduction of Na V 1.7 trafficking to selectively reduce the activity of ascending pain pathway neurons that promote perception of pain. To aid successful implementation of this strategy into clinical practice, future studies will explore long-term effects of antagonizing Na V 1.7 trafficking on both ascending and descending pain pathways. Endogenous opioids function as effectors of descending pain pathways 80 and a recent study has linked knockout of DRG Na V 1.7 expression and reduction of intracellular DRG sodium concentration to increased endogenous opioid mRNA expression. 59 The study used opioid receptor antagonists to conclude that endogenous opioid production contributes to Na V 1.7 knockout-mediated congenital insensitivity to pain. Na V -endogenous opioid signaling pathways have not been completely elucidated but may permit Na V 1.7 trafficking antagonists to engage a secondary response through endogenous opioid production. This arrangement could enhance the analgesic function of CRMP2 SUMOylation-targeting therapies.
Despite the importance of SUMOylation in regulating diverse biological systems and diseases, only a few small-molecule inhibitors of SUMOylation have been reported. These include mostly natural products such as ginkgolic acid, 27 kerriamycin B, 28 spectomycin B1, chaetochromin A, and viomellein 35 ; however, none of these are commercially available. With respect to diseases, Ubc9 blockers have been used in cancer therapy because Ubc9 is overexpressed in several cancers, 47, 60, 61 and many tumorigenesis-associated proteins are reported to be SUMOylated. 62 As an example, human genome studies provide striking evidence for a link between the impaired SUMOylation of a single transcription factor and a predisposition to cancer. 3, 92 All hitherto-reported strategies are therapeutically impractical because targeting the SUMOylation machinery-either E1 or E2-would generate nonselective antagonists of essential biological processes. Our study is the first to design a SUMOylation inhibitor (ie, the t-CSM peptide) against a singular protein-protein interaction (ie, Ubc9-CRMP2) that is expected to allosterically modulate Na V 1.7 activity. Because the modification of CRMP2 by SUMOylation to selectively regulate Na V 1.7 membrane expression is conserved in human sensory neurons, 19 finding a selective CRMP2 SUMOylation inhibitor would have a high likelihood of clinical translation.
Importantly, our approach does not target Ubc9, which is the necessary E2-conjugating enzyme for SUMOylation of several protein targets. Ubc9 knockout mice are embryonic lethal, 68 and global decreases in SUMOylation are implicated in cognitive dysfunction. 46 Thus, in an effort to find a selective "druggable" pocket in CRMP2 close to the SUMOylation site on residue K374, we generated an in silico model of CRMP2 with Ubc9-SUMO (Fig.  13A) . The crystal structure of the mammalian guanosine triphosphate (GTP)ase-activating protein (RanGAP1), one of the first proteins reported to be covalently linked to SUMO, 50 ) . Residue K374 was then used as an anchor to refine the complex using molecular minimization with the Schrodinger suite and is in proximity to Ubc9 active site C93 48 ( Figs. 13B and C) . The identified potential "hot spot" CRMP2 residues include (1) K23; (2) W366; (3) V371 of CRMP2, which form a carbonyl backbone amide H-bond with A131 of Ubc9; (4) M375; (5) E377; (6) Q379; and (7) R440 of CRMP2, which form a salt bridge with E132 of Ubc9 (Fig.  13C) . It has been shown that single mutations in A131 or E132 significantly affect Ubc9's interaction with target proteins-the tumor suppressor protein p53, the ubiquitin-activating enzyme E1B, and promyelocytic leukemia protein-and reduce their SUMOylation. 48 Thus, targeting this CRMP2 pocket using in silico docking may prove useful in discovering small molecules disrupting CRMP2-Ubc9 interaction in the context of pain relief.
That CRMP2 is implicated in neuropathic pain can be surmised from recent work, which demonstrates that there is a substantial increase in the amount of SUMOylated CRMP2 in sensory neurons and spinal cord dorsal horn in rodent models of chronic pain. 10, 57, 64, 78 This finding is congruent with transcriptomic data demonstrating an enrichment of CRMP2 in nociceptors, 79 further underscoring the importance of targeting CRMP2 under these conditions. Validating the importance of SUMOylation of CRMP2 as a pathologic event in chronic pain, we previously observed that transient expression of a SUMO-null CRMP2, through spinal administration of plasmid encoding CRMP2 K374A, significantly attenuated pain behavior in SNI animals. 64 Here, we extend these findings using a structurally guided, rationally designed CRMP2 SUMO "decoy" peptide that recapitulates observations made with the genetic manipulation with the reversal of thermal and tactile hypersensitivity when administered to animals with SNI. Notably, the peptide failed to reverse visceral pain, findings consonant with the reported lack of Na V 1.7 dependency in this acute inflammatory model. 36, 52 These data consolidate the hypothesis that targeting CRMP2 SUMOylation to allosterically regulate Na V 1.7, and by extension, Na V 1.7-dependent acute, inflammatory, and neuropathic pain is a viable alternative strategy. A potential limitation of our study is that not all pain is Na V 1.7-dependent; bone cancer pain and chemotherapy (ie, oxaliplatin-evoked) mechanical and cold allodynia occur normally in Na V 1.7-null mutant mice. 58 Notwithstanding these limitations, our work suggests that targeting CRMP2 modifications can be used to control ion channels implicated in neuropathic pain. Focusing on another CRMP2 modification, phosphorylation by cyclin-dependent kinase 5 (Cdk5), we demonstrated that inhibiting phosphorylation by Cdk5 on residue S522 with (S)-lacosamide, an inactive stereoisomer of the clinically used antiepileptic drug (R)-lacosamide (Vimpat), translated into a decrease of calcium influx through presynaptic N-type voltage-gated calcium channels. 66 This inhibition resulted in mitigation of thermal hypersensitivity and mechanical allodynia in model of postoperative, neuropathic, pain, and cephalic pain. 63, 65 (S)-lacosamide was also reported to affect Na V 1.7-mediated sodium currents in a CRMP2-dependent manner because CRMP2 SUMOylation is dependent on its previous phosphorylation by Cdk5. 67 CRMP2 phosphorylation by Cdk5 at residue S522 plays other roles such as that in dendritic development. 69 Consequently, the strategy proposed here of disrupting CRMP2
SUMOylation, an event downstream of Figure 12 . The intrathecal administration of t-CSM did not result in significant deficit in motor coordination as tested using the rotarod performance test. t-CSM (20 mg/5 mL, intrathecally [i.t.]) was evaluated for motor deficits using the rotarod performance test using naive (A) or SNI (B) rats. Vehicle-treated animals and t-CSM-treated animals remained on the rotarod for an average of 180 6 0 seconds over a 24-hour period (P . 0.01, 2-way ANOVA, n 5 6-8). t-CSM did not affect motor performance at any time point measured in the SNI rats (P . 0.01, 2-way ANOVA, n 5 6-8). ANOVA, analysis of variance.
phosphorylation, may represent a more incisive approach for "fine-tuning" CRMP2 modifications to control ion channels implicated in pain. The demonstration of a CSM "decoy" peptide in reducing Na V 1.7-mediated sodium influx and reversing SNI-related pain behaviors, combined with the structural modeling-based identification of a pocket harboring CRMP2's SUMOylation motif, sets the stage for experimental (ALPHA, MST) and computational (in silico docking) screening of ligands/ molecules that will biochemically and functionally target CRMP2's SUMOylation to reduce Na V 1.7 currents and reverse neuropathic pain.
